Drugs / M3541
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03225105 | Sep 2017 → Sep 2019 | cancer | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M3541 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03225105 ↗ |
| Action | Inhibit | “selective inhibitor of ATM” PMID 35150356 ↗ Feb 2022 |
| Route | Oral | “M3541 is an orally administered selective inhibitor of ATM.” PMID 35150356 ↗ Feb 2022 |
| Target | ATM | “selective inhibitor of ATM” PMID 35150356 ↗ Feb 2022 |